Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)

“I do think this [approval] represents a step forward for patients who have the FLT3 mutation in association with their [AML] over the previous standard, midostaurin [Rydapt],” study author @MikkaelSekeres, MD, said in an interview with CancerNetwork ahead of the approval. https://t.co/nqtM6JI5dz (@CancerNetwrk)

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in HCC @OncologyAdvance https://t.co/xit1v39BjF ❓What should we do and what can we expect for 2nd line therapy 🌍RWD suggest: 👉AtzeBev > Lenva 👉Lenva > ICI @myESMO @ILCAnews @EASLedu… https://t.co/ALX315Novm (@ArndtVogel)

Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnZcwj @JCOOP_ASCO (@urotoday)

According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)

15a/16 #TumorBoardTuesday 🧑🏼‍🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (@katy_beckermann)

- CML imatinib (& other rarer dz) - EGFR, ALK, ROS, & others in NSCLC - HER2 in breast, gastric Ca - BRAF/MEK in melanoma, thyroid & others - FLT3, IDH in AML (tho trial designs variable) - PSMA in Lu-PSMA @Dr_R_Kurzrock (@Eddie_Cliff)

🗞️ Published in @TheLancetOncol and co-authored by VHIO’s @crisuarez08, results from the single-arm phase II KEYNOTE-B61 clinical trial support the use of pembrolizumab plus lenvatinib in patients with previously untreated advanced non-clear cell renal cell carcinoma. ➕… https://t.co/qUn891LZBA (@VHIO)

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/yU9CWV30fx (@OncLive)

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/RQML5zNQnC (@OncLive)

The sustained OS benefit observed with pembrolizumab and lenvatinib in the CLEAR study solidifies the doublet’s use as a preferred option for the frontline treatment of patients with advanced RCC. @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/Jmjj0bMNuC (@OncLive)

We spoke with @ChungHanLee3 from @MSKCancerCenter on the use of lenvatinib and pembrolizumab in patients with RCC. #kicsm | @kidneycan (@CancerNetwrk)

Guess who stopped by? @ChungHanLee3, of @MSKCancerCenter! Thanks for speaking with us about the final results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell RCC #kcsm @kidneycan (@OncLive)

⁦@DrChoueiri⁩ discussing SAMETA - p3 trial for savolitinib+durva vs sunitinib vs durva in pts with MET-driven papillary RCC ⁦@kidneycan⁩ #KCRS23 (@MosheOrnsteinMD)

S3: Trials In Progress ⚡️ SAMETA A Phase 3 Study of Savolitinib + Durva vs Sunitinib vs Durva Alone in Patients with MET-Driven Advanced Papillary RCC @DrChoueiri @DanaFarber_GU @kidneycan #KCRS23 (@MikeSerzanMD)

Encouraging results in non-clear cell RCC. However, efficacy appears to be lower in the chromophobe subtype and in the PDL1-negative group. In the chromophobe type, lenvatinib + everolimus may be more effective. (@dr_yakupergun)

⭐️KEYNOTE-B61 single-arm, ph 2 trial of first-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma, 78 of 158 patients had a confirmed objective response (49%; 95% CI 41–57) @TheLancetOncol @OncoAlert @AlbigesL https://t.co/59ZG4tZHVI (@VivekSubbiah)

After a great presentation at @ASCO #ASCO23, full paper just out @TheLancetOncol Keynote B61: 🚹Non-clear cell mRCC 💊Pembrolizumab+Lenvatinib 1st line 🎯ORR:49%, CR:6% @DrChoueiri @AlbigesL @ChungHanLee3 @OncoAlert @DrYukselUrun https://t.co/pHrrelHSLb (@yekeduz_emre)

Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23 full text: https://t.co/QioxQEiKho Thanks to all who change rareRCC pts Tx! (@AlbigesL)

➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)

The combination of pembrolizumab + axitinib continued to improve OS, PFS, & ORR over sunitinib monotherapy in patients with treatment-naïve clear cell RCC. @brian_rini @VUMChealth #kcsm https://t.co/tKcszvDygl (@OncLive)

1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)

Great talk by @NitinJainMD on T-ALL ➡️ CAR-T cells being optimized with promising results ➡️ Rationale for inhibition of BCL-2 BCL-xl ➡️ LCK in 40% of T-ALL sensitive to dasatinib/ponatinib. Clinical trial at @MDAndersonNews with chemo-VEN-ponatinib #leusm #ALL @_MDEducation (@FadiHaddad_MD)

Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/4CP5RKH4Vq (@OncLive)

Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/2uj87xQ7pv (@OncLive)

According to Lori Muffly, #briquilimab with low-dose total body radiation and fludarabine was safe and well-tolerated for patients with #MDS and #AML undergoing alloHCT. @StanfordMed @StanfordCancer @LoriMuffly https://t.co/19chBNCxQj (@TargetedOnc)

For me this question is crystal clear. There is a wealth of evidence showing that GO provides a large significant improvement in OS in patients with CBF-AML. Benefit of midostaurin is modest overall, and data is limited in patients with CBF-AML. So 7+3 + GO or FLAG-GO, no doubt. (@grichardmd)

Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/PJMI5i2fqE (@OncLive)

The combination of pembrolizumab + axitinib continued to improve OS, PFS, & ORR over sunitinib monotherapy in patients with treatment-naïve clear cell RCC. @brian_rini @VUMChealth #kcsm https://t.co/YN4Oz9QJRP (@OncLive)

Lenvatinib Plus Pembrolizumab vs Regorafenib or TAS for Previously Treated mCRC: Phase 3 LEAP-017 Study at #WCGIC2023 👉mOS: 9.8 vs 9.3 mo 👉There is some activity, but⛔️ 👉IO in MSS CRC remains a challenge... @WCGIC @myESMO @OncoAlert (@ArndtVogel)

.@DrChoueiri and Rohit Gosain, MD, reviewed results from the phase 3 CheckMate 9ER trial which asseed nivolumab plus cabozantinib vs sunitinib in patients with renal cell carcinoma. #rccsm https://t.co/Sahrg8aNOy (@CancerNetwrk)

Thank you @CancerTherAdvsr for featuring our article on HRQOL outcomes w 2 different starting doses of lenvatinib in combination w everolimus for previously treated RCC Grateful for this opportunity @montypal @OncJournal @DrDanielHeng @docjavip @cdanicas https://t.co/eJ3z4eA5oq (@crisbergerot)

Eric A. Singer, MD, discusses the #FDA approval of adjuvant sunitinib and data that support the approval for patients with high-risk renal cell carcinoma. #RCC #kcsm | @eric_facs @OSUCCC_James https://t.co/qaR5uc0Poh (@TargetedOnc)

Pembro & Lenvatinib can be challenging: Was there any toxicity data? Worried about this in a relapsed mesothelioma patient group (@tnewsomdavis)

At @ASCO23, @DrRanaMcKay met with @ChungHanLee3 to discuss the latest data on KEYNOTE-B61 for first-line #lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma. Watch now: https://t.co/awjZeCxkRb (@GUOncologyNow)

Exactly, often "not enough events occurred at time of data cut off for difference in OS to reach statistical significance" is reported as "no difference in OS". In GU, S-TRAC of adjuvant sunitinib in RCC clearly fits the definition in the slide, but others are more nuanced. (@AtishChoudhury)

8/19 #TumorBoardTuesday #Sarcoma 👩🏻‍🏫Mini tweetorial 5👨🏻‍🏫 📰 Extra! Extra! 📰 ⬆️ TTP with sunitinib (SU) vs placebo 👍🏽 FDA approves SU for IM-resistant unresectable/adv #GIST 📚@DrSarcoma @CFletcherMD https://t.co/lspox5XwDG (@SteveBialickDO)

11/19 #TumorBoardTuesday #Sarcoma 👩🏻‍🏫Mini tweetorial 8👨🏻‍🏫 ✨INVICTUS (cont’d)✨ 📌Ripretinib (RI) ▪️mPFS 6.3m (RI) vs 1.0m (placebo); p<0.0001 ▪️common AEs: 🧑‍🦲,💪🏼😫,🤢,😴 📚@jeanyvesblay @DrCeSarcoma https://t.co/i4ec7ZBOZE (@SteveBialickDO)

10/19 #TumorBoardTuesday #Sarcoma 👩🏻‍🏫Mini tweetorial 7👨🏻‍🏫 ✨INVICTUS✨ 📌Ripretinib (RI), a switch-control TKI 🙌🏼shows efficacy/safety in 4L+ adv #GIST ▪️ph 3, multicenter ▪️dbl-blnd ➡️ plcbo-ctrl trial ▪️2:1 RI vs plcbo after prog (or intol) with IM, SU, & RE (@SteveBialickDO)

Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnYEGL @JCOOP_ASCO (@urotoday)

At #ASCO23, @WallisCJD interviewed @brian_rini on an abstract focused on KEYNOTE-426, which revealed long-term survival data on pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell #RCC. Watch now: https://t.co/mUQplYnsxo (@GUOncologyNow)

3-year follow-up #CheckMate9ER trial: Nivolumab + cabozantinib vs sunitinib for first-line treatment of advanced #RenalCellCarcinoma. @BurottoMauricio @bradfordhill_cl joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/fAh3th9BZQ @ExelixisInc @CABOMETYX (@urotoday)